Laboratory of Experimental Thrombosis, Institute of Experimental Medicine (CONICET), National Academy of Medicine, Buenos Aires, Argentina.
Service of Hematology, Bazterrica Clinic, Buenos Aires, Argentina.
Thromb Res. 2014 Feb;133(2):235-43. doi: 10.1016/j.thromres.2013.11.028. Epub 2013 Dec 1.
Platelets express Toll-like receptors (TLRs) that recognise molecular components of pathogens and, in nucleated cells, elicit immune responses through nuclear factor-kappaB (NF-κB) activation. We have shown that NF-κB mediates platelet activation in response to classical agonists, suggesting that this transcription factor exerts non-genomic functions in platelets. The aim of this study was to determine whether NF-κB activation is a downstream signal involved in TLR2 and 4-mediated platelet responses.
Aggregation and ATP release were measured with a Lumi-aggregometer. Fibrinogen binding, P-selectin and CD40 ligand (CD40L) levels and platelet-neutrophil aggregates were measured by cytometry. I kappa B alpha (IκBα) degradation and p65 phosphorylation were determined by Western blot and von Willebrand factor (vWF) by ELISA.
Platelet stimulation with Pam3CSK4 or LPS resulted in IκBα degradation and p65 phosphorylation. These responses were suppressed by TLR2 and 4 blocking and synergised by thrombin. Aggregation, fibrinogen binding and ATP and vWF release were triggered by Pam3CSK4. LPS did not induce platelet responses per se, except for vWF release, but it did potentiate thrombin-induced aggregation, fibrinogen binding and ATP secretion. Pam3CSK4, but not LPS, induced P-selectin and CD40L expression and mixed aggregate formation. All of these responses, except for CD40L expression, were inhibited in platelets treated with the NF-κB inhibitors BAY 11-7082 or Ro 106-9920.
TLR2 and 4 agonists trigger platelet activation responses through NF-κB. These data show another non-genomic function of NF-κB in platelets and highlight this molecule as a potential target to prevent platelet activation in inflammatory or infectious diseases.
血小板表达 Toll 样受体 (TLR),可识别病原体的分子成分,并在有核细胞中通过核因子-κB (NF-κB) 激活引发免疫反应。我们已经表明,NF-κB 介导血小板对经典激动剂的激活,这表明该转录因子在血小板中发挥非基因组功能。本研究旨在确定 NF-κB 激活是否是 TLR2 和 TLR4 介导的血小板反应的下游信号。
用 Lumi-aggregometer 测量聚集和 ATP 释放。通过流式细胞术测量纤维蛋白原结合、P-选择素和 CD40 配体 (CD40L) 水平以及血小板-中性粒细胞聚集体。通过 Western blot 测定 IκBα 降解和 p65 磷酸化,通过 ELISA 测定 von Willebrand 因子 (vWF)。
Pam3CSK4 或 LPS 刺激血小板导致 IκBα 降解和 p65 磷酸化。这些反应被 TLR2 和 TLR4 阻断抑制,并与凝血酶协同。Pam3CSK4 触发聚集、纤维蛋白原结合和 ATP 和 vWF 释放。LPS 本身不能诱导血小板反应,除了 vWF 释放外,但它确实增强了凝血酶诱导的聚集、纤维蛋白原结合和 ATP 分泌。Pam3CSK4 但不是 LPS 诱导 P-选择素和 CD40L 表达和混合聚集体形成。除了 CD40L 表达外,所有这些反应都在 NF-κB 抑制剂 BAY 11-7082 或 Ro 106-9920 处理的血小板中受到抑制。
TLR2 和 TLR4 激动剂通过 NF-κB 触发血小板激活反应。这些数据表明 NF-κB 在血小板中具有另一种非基因组功能,并强调了该分子作为预防炎症或感染性疾病中血小板激活的潜在靶点。